While employers fall on a spectrum when it comes to knowledge and understanding of biosimilars, there does remain a need to educate them, as well as for them to educate their employees, said Margaret Rehayem, vice president, National Alliance of Healthcare Purchaser Coalitions.
While employers fall on a spectrum when it comes to knowledge and understanding of biosimilars, there does remain a need to educate them, as well as for them to educate their employees, said Margaret Rehayem, vice president, National Alliance of Healthcare Purchaser Coalitions.
Transcript
How comfortable and confident in biosimilars are employers to push for these products over the reference? Are you still needing to provide education so employers understand the benefits of biosimilars?
There is still a need for education for employers. I think, employers really fall across the spectrum when we're talking about biosimilars. Some of them have actually not only put them on formulary but are willing to go to their health plan, their [pharmacy benefit manager] and actually say, “This is what I want.” And then we've had employers that are still trying to figure out where biosimilars can or should show up in their contract. There's really this broad spectrum right now that we're working with. Therefore, I think there still is a need for education.
We actually recently completed a learning collaborative where we had that broad spectrum within the same collaborative. It was a very exciting time just to hear those that were more well versed in those that were still learning willing to have discussions with one another on this topic. We're still going to continue to move forward with education and meet our coalitions where they're at with their members.
Do employers need to provide more education for employees on biosimilars, and what has that process looked like?
It's interesting, you bring that up, because this was a common concern for many of the employers that we've talked to is being able to communicate the right information that's out there. They're very concerned about the direct-to-consumer advertising is happening now with a lot of different types of drugs. They have to not only put the right information out there, but they have to counteract some of the misinformation that's out there about drugs. It's something that I think employers are very concerned about. They do want to get the right information out there. But they also need to make sure that they're coordinating with what they do have on formulary, so that they're giving the best information to their employees and families.
Disparities in Biomarker Testing Impact Nonsquamous NSCLC Outcomes: Surbhi Singhal, MD
September 6th 2025Surbhi Singhal, MD, of the University of California Davis, discussed disparities in biomarker testing among patients diagnosed with stage IV nonsquamous non–small cell lung cancer (NSCLC).
Read More
Infertility Coverage Boosts ART Use and Pregnancy Success: Richard A. Brook, MS, MBA
August 26th 2025In this episode, Richard A. Brook, MS, MBA, discusses his study showing that infertility treatment coverage increases assisted reproductive technology (ART) use and improves pregnancy outcomes.
Listen
Rideshare Cuts Colon Cancer Deaths, Saves Costs After Abnormal FIT, Study Finds
September 4th 2025A study finds that $100 rideshare rides for follow-up colonoscopy after fecal immunochemical test (FIT) doubled completion rates, reduced colorectal cancer (CRC) deaths, and lowered health care costs.
Read More
Economic Burden Is Greater Among Patients With Ovarian Cancer Receiving BRCA Testing
September 4th 2025Patients with ovarian cancer who undergo BRCA testing face higher health care resource utilization (HCRU) and costs but are more likely to receive genomically targeted therapies and progress to later lines of treatment (LOT).
Read More